SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

Tuesday, April 15, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

DUBLIN, Calif., April 14 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced as part of a series ofpresentations at the 2008 AACR Annual Meeting that MP-470 effectivelysensitizes prostate and breast cancer cells to erlotinib (Abstract No. 671).

Entitled, "Inhibition of erlotinib resistance on HER-family tyrosinekinases by combination with MP-470, a multi-targeted TK inhibitor in prostateand breast cancer," the poster highlights data indicating that the combinationof MP-470 and erlotinib inhibits the binding of the p85 subunit of PI3K, andhas a greater impact than either agent alone in reducing phosphorylation ofAkt, ERK1/2, EGFR/HER1, HER2/Neu, and HER3.

"These data build upon previous results showing that MP-470 exhibitsanti-tumor activity in breast and prostate cancer cells," said Dr. DavidBearss, SuperGen's Vice President and Chief Scientist. "The fact that MP-470in combination with erlotinib effectively suppressed the HER pathway suggeststhat concurrent administration of both compounds could represent a newtreatment for prostate and breast cancers. We will continue to explore thissynergy as we develop further MP-470."

Copies of the 2008 AACR Annual Meeting poster presentations will beavailable in the pipeline section of SuperGen's Web site

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factorsthat might cause the company's results to differ materially from thoseexpressed or implied by such forward-looking statements include, but are notlimited to, the ability to discover, develop and move target compounds intoclinical development and other risks and uncertainties detailed from time totime in the company's filings with the Securities and Exchange Commissionincluding its most recently filed Form 10-Q and 10-K. SuperGen, Inc.undertakes no duty to update any of these forward-looking statements toconform them to actual results.Contacts Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications & Business Manager, Investor Development Relations Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: E-mail:

SOURCE SuperGen Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store